Safety and efficacy of tDCS as an early augmentation (add on to medications) strategy in management of Obsessive Compulsive Disorder
Phase 3
- Conditions
- Health Condition 1: F422- Mixed obsessional thoughts and acts
- Registration Number
- CTRI/2023/02/049682
- Lead Sponsor
- King Georges Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Age: 18 years to 50 years
2. Informed consent to participate in the study
3. Symptomatic (Y-BOCS Score >16) patients of OCD diagnosed as per ICD-10 DCR.
4. Drug free for at least past 1 month
Exclusion Criteria
1. Medical comorbidities that need immediate attention
2. Any contraindication to tDCS
3. Any other psychiatric comorbidity (except Depressive disorder, Anxiety disorder and tobacco use disorder)
4. Patient resistant to Fluoxetine (If previously treated)
5. Patient currently on any Psychotherapy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction of Y-BOCS scores (Obsessions, compulsions, total) at 2 weeks, 4 weeks and 6 weeksTimepoint: Assesment of Y-BOCS scores (Obsessions, compulsions, total) at baseline, 2 weeks, 4 weeks and 6 weeks
- Secondary Outcome Measures
Name Time Method 1. t-DCS side effect checklist <br/ ><br>2. Change in subscales scores of Hamilton Rating Scale for Depression (HAM-D) and Hamilton Rating Scale for Anxiety (HAM-A)Timepoint: 1) tDCS side effects assessed after 10 sessions of tdcs. <br/ ><br>2) HAM-D and HAM-A scales at baseline, 2 weeks, 4 weeks and 6 weeks.